{
    "root": "947517b9-20f4-42ac-bd68-44c5e249ea27",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250312",
    "ingredients": [
        {
            "name": "ZEA MAYS (CORN) STARCH",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CI 47005",
            "code": "35SW5USQ3G"
        },
        {
            "name": "CI 45430",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "CI 77891",
            "code": "15FIX9V2JP"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        }
    ],
    "indications": "Phentermine Hydrochloride, USP 15 mg and 30 mg is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m\n \n  2, or greater than or equal to 27 kg/m\n \n  2in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n\n \n                  Below is a chart of Body Mass Index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.\n                  \n                     \n                  \n                  The limited usefulness of agents of this class, including Phentermine hydrochloride, [\n \n  see CLINICAL PHARMACOLOGY (\n                     \n                        12.1\n                     \n                     ,\n                     \n                        12.2\n                     \n                     )] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. ( 2.1 ) Late evening administration should be avoided (risk of insomnia). ( 2.1 ) Phentermine Hydrochloride can be taken with or without food. ( 2.1 ) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ) ( 2.2 )",
    "warningsAndPrecautions": "Product:    50090-0119\n                  NDC:    50090-0119-0   30 CAPSULE in a BOTTLE\n                  NDC:    50090-0119-3   7 CAPSULE in a BOTTLE\n                  NDC:    50090-0119-4   28 CAPSULE in a BOTTLE",
    "adverseReactions": "History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n                     During or within 14 days following the administration of monoamine oxidase inhibitors\n                     Hyperthyroidism\n                     Glaucoma\n                     Agitated states\n                     History of drug abuse\n                     Pregnancy\n  \n   [see Use in Specific Populations (\n   \n    8.1)]\n  \n   \n                     \n                     Nursing\n  \n   [see Use in Specific Populations (\n   \n    8.3)]\n  \n   \n                     \n                     Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines"
}